Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants
Completed · Phase 2 · NCT04520451
Conditions: Immunoglobulin G4 Related Disease
At a glance
- Research payments reported, 2025
- $434,564
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 27
About the trial
- Sponsor
- Principia Biopharma, a Sanofi Company (with Massachusetts General Hospital)
- Tested
- rilzabrutinib (drug), Glucocorticoids (drug)
- Dates
- Started 2020-08-22; completion 2024-10-15
- Results posted
- Not yet
This is a Phase 2a, multi-center, open-label, two-arm study of approximately 25 patients with active IgG4-related disease (IgG4-RD). The two arms include (1) Experimental: rilzabrutinib with glucocorticoids and (2) Active Comparator: glucocorticoids only.
From ClinicalTrials.gov, last updated 2025-10-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $434,564 in research payments for this study in 2025 (8 payments).
Products named: Wayrilz
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.